tiprankstipranks
Trending News
More News >
Oxford Nanopore Technologies PLC (GB:ONT)
LSE:ONT
Advertisement

Oxford Nanopore Technologies PLC (ONT) AI Stock Analysis

Compare
128 Followers

Top Page

GB:ONT

Oxford Nanopore Technologies PLC

(LSE:ONT)

Rating:67Neutral
Price Target:
189.00p
▼(-7.44%Downside)
Oxford Nanopore Technologies PLC's stock score reflects a strong technical uptrend and positive earnings call guidance, which are slightly offset by financial challenges and valuation concerns. The company's strategic positioning and growth potential are notable, but profitability and cash flow issues remain key risks.
Positive Factors
Financial Guidance
The company reaffirmed its near-term and medium-term financial guidance, signaling confidence in its strategic direction.
Market Presence
Research revenue increased year-over-year in EMEA and APAC, demonstrating strong market presence.
Product Performance
Strong performance was driven primarily by continued adoption of the PromethION product range.
Negative Factors
Competition
The entrenched nature of Illumina in the sequencing workflow and increasing competition from companies like Roche present challenges.
Funding Environment
There is a significant headwind due to the tight funding environment exacerbated by expected cuts to NIH funding.
Growth Guidance
The growth guidance of 20-23% for 2025 is below previous consensus expectations, putting further pressure on the company's growth targets.

Oxford Nanopore Technologies PLC (ONT) vs. iShares MSCI United Kingdom ETF (EWC)

Oxford Nanopore Technologies PLC Business Overview & Revenue Model

Company DescriptionOxford Nanopore Technologies plc develops and commercializes a technology platform using nanopore-based sensing for the analysis of various types of molecules. The company offers MinION, a portable device for deoxyribonucleic acid and ribonucleic acid sequencing; GridION, a self-contained benchtop device for running and analyzing up to five MinION or Flongle flow cells; MinION Mk1C for basecalling and data analysis, touchscreen operation, and wireless connectivity; Flongle, an adapter for use in MinION or GridION devices to attach a Flongle flow cell; GridION Mk1, a benchtop nanopore sequencer; PromethION 2 Solo and PromethION 2, a low-cost access to high-yield PromethION sequencing; PromethION 24 and PromethION 48 benchtop nanopore-based sequencers for multiple users to deliver multi-sample and multi-experiment sequencing results; and VolTRAX, an USB-powered device, which automates laboratory processes upstream of nanopore sequencing. It also provides MinKNOW, a software that offers data acquisition, real-time analysis and feedback, local basecalling, and data streaming; Basecalling tools to determine the identity and order of bases on the DNA/RNA molecule; EPI2ME, a cloud-based data analysis platform for end-to-end analysis of nanopore data in real time; and EPI2ME Labs, a bioinformatics solution to assist users in developing their skills and confidence in the analysis of their nanopore-based sequencing data. In addition, the company is developing MinION Mk1D; Ubi; Plongle; and SmidgION products. It sells its products online. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies Limited in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is based in Oxford, the United Kingdom.
How the Company Makes MoneyOxford Nanopore Technologies PLC generates revenue primarily through the sale of its sequencing devices and consumables required for the sequencing process. These products include the MinION, GridION, and PromethION platforms, which cater to different throughput needs and use cases. The company also earns money by providing software solutions and support services that enhance the functionality and user experience of their sequencing technologies. Additionally, ONT engages in collaborations and partnerships with research institutions, healthcare providers, and other organizations, which can lead to joint ventures or licensing agreements that contribute to their revenue. Their ability to innovate and cater to a broad spectrum of market needs, from academic research to clinical diagnostics, plays a significant role in their financial performance.

Oxford Nanopore Technologies PLC Earnings Call Summary

Earnings Call Date:Mar 04, 2025
(Q4-2024)
|
% Change Since: 94.29%|
Next Earnings Date:Sep 02, 2025
Earnings Call Sentiment Neutral
Oxford Nanopore reported strong revenue growth and cash positions, driven by increased demand for PromethION and new product launches. However, the company faces significant challenges due to U.S. federal funding uncertainties and currency headwinds, which could impact future growth. Despite these challenges, the company remains confident in its strategic positioning and opportunities in applied markets.
Q4-2024 Updates
Positive Updates
Strong Revenue Growth
Oxford Nanopore reported FY 2024 revenues at GBP 183.2 million, representing an 11.1% increase at constant currency and 23.3% on an underlying constant currency basis, in line with their guidance of 20% to 30% growth.
PromethION Flow Cell Utilization Increase
PromethION flow cell utilization increased by 36% from the first half to the second half of 2024, indicating higher demand for the company's sequencing technology.
Strong Cash Position
The company ended 2024 with a strong balance sheet, holding GBP 403.8 million in cash, supported by an GBP 80 million raise from new and existing investors in the second half.
Significant Advances in Applied Markets
The applied industrial segment grew over 40%, with significant contracts in plasmid sequencing and synthetic biology markets, displacing traditional methods like Sanger sequencing.
Innovative Product Launches
GridION Q-Line launched in 2024, with plans to roll out PromethION Q-Line in 2025, coupled with the ElysION platform for regulated workflows.
Negative Updates
Challenges with U.S. Federal Funding and Export Control Restrictions
The company faces headwinds due to U.S. federal funding uncertainties and export control restrictions, particularly affecting NIH funding, with significant impacts expected on future revenue.
Weakness in MinION Revenues
MinION revenues declined by nearly 10% due to the removal of the Mk1C device, affecting the overall growth in consumables.
Currency Headwinds
Currency fluctuations represented a GBP 5.3 million headwind, impacting reported growth figures.
Operational Challenges
The company acknowledged operational challenges and opportunities for improvement as it matures its processes and business operations.
Company Guidance
In the call, Oxford Nanopore provided comprehensive guidance for 2025, projecting revenue growth of 20% to 23% on a constant currency basis, driven by strong demand for their technology despite potential challenges like U.S. federal funding uncertainties and export control restrictions. They anticipate a gross margin of approximately 59%, representing a year-on-year increase of 100 basis points. The company expects overall growth in adjusted costs to be at the low end of their medium OpEx guidance. Medium-term goals include maintaining a compound annual growth rate of over 30%, targeting a gross margin greater than 62%, and achieving adjusted EBITDA breakeven by 2027 and cash flow positivity by 2028. Oxford Nanopore is focusing on expanding into applied industrial, biopharma, and clinical markets, with biopharma projected to constitute 20% to 30% of revenues by 2027. The company's recent pricing model changes could enhance revenue and margins, with potential mid-single-digit revenue growth and 50 to 100 basis points margin improvement over the medium term.

Oxford Nanopore Technologies PLC Financial Statement Overview

Summary
Oxford Nanopore Technologies PLC shows consistent revenue growth and a solid equity position. However, persistent unprofitability and negative cash flows underscore challenges in cost management and cash flow sustainability.
Income Statement
55
Neutral
Oxford Nanopore Technologies PLC shows a consistent revenue growth trend, with a 7.95% increase from 2023 to 2024. However, the company remains unprofitable, reflected by negative EBIT and net income margins, indicating ongoing challenges in cost management and profitability.
Balance Sheet
60
Neutral
The company maintains a solid equity base with an equity ratio of 79.03% in 2024, suggesting financial stability. However, the high debt-to-equity ratio of 0.08 indicates potential leverage concerns, although manageable due to strong equity.
Cash Flow
50
Neutral
Operating cash flow remains negative, highlighting cash management challenges. Despite an improvement in free cash flow to net income ratio, free cash flow remains negative, suggesting ongoing cash flow constraints that may impact future growth initiatives.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue183.19M169.67M198.60M133.66M113.86M
Gross Profit105.39M90.48M123.81M73.19M46.88M
EBITDA-93.09M-105.71M-49.67M-140.34M-55.07M
Net Income-146.19M-154.51M-91.03M-167.61M-61.24M
Balance Sheet
Total Assets742.05M777.06M823.89M841.87M281.21M
Cash, Cash Equivalents and Short-Term Investments338.37M270.05M476.19M618.47M80.86M
Total Debt45.96M41.66M34.10M24.80M23.63M
Total Liabilities155.71M133.21M130.33M137.89M95.28M
Stockholders Equity586.34M643.85M693.56M703.98M185.93M
Cash Flow
Free Cash Flow-123.83M-164.59M-91.62M-84.64M-90.28M
Operating Cash Flow-109.89M-137.30M-49.39M-53.83M-63.81M
Investing Cash Flow15.03M-61.79M-65.79M-161.99M-26.94M
Financing Cash Flow73.58M64.73M-13.71M622.90M158.58M

Oxford Nanopore Technologies PLC Technical Analysis

Technical Analysis Sentiment
Positive
Last Price204.20
Price Trends
50DMA
135.72
Positive
100DMA
123.66
Positive
200DMA
130.89
Positive
Market Momentum
MACD
14.61
Negative
RSI
85.91
Negative
STOCH
98.69
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ONT, the sentiment is Positive. The current price of 204.2 is above the 20-day moving average (MA) of 154.32, above the 50-day MA of 135.72, and above the 200-day MA of 130.89, indicating a bullish trend. The MACD of 14.61 indicates Negative momentum. The RSI at 85.91 is Negative, neither overbought nor oversold. The STOCH value of 98.69 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:ONT.

Oxford Nanopore Technologies PLC Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
£1.81B-23.77%7.97%12.94%
61
Neutral
£343.08M8.7211.74%38.80%
52
Neutral
$7.61B0.10-63.03%2.08%16.34%0.32%
46
Neutral
£101.18M167.16%-100.00%-23.91%
44
Neutral
£135.18M-73.02%
$552.20M-66.23%
39
Underperform
£150.49M-95.28%84.39%-41.02%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:ONT
Oxford Nanopore Technologies PLC
204.20
70.30
52.50%
GB:AVCT
Avacta Group plc
40.50
-30.50
-42.96%
GB:PRTC
PureTech Health
142.80
-30.40
-17.55%
GB:SCLP
Scancell Holdings
9.75
-4.75
-32.76%
OXBDF
Oxford BioMedica
5.27
0.79
17.63%
GB:4BB
4basebio UK Societas
970.00
-505.00
-34.24%

Oxford Nanopore Technologies PLC Corporate Events

Business Operations and StrategyFinancial Disclosures
Oxford Nanopore Reports Strong H1 2025 Performance, Maintains Full-Year Guidance
Positive
Jul 21, 2025

Oxford Nanopore Technologies reported a robust performance in the first half of 2025, with a 28% increase in revenue to approximately £105 million, driven by strong growth in their PromethION product range and significant progress in both Research and Applied markets. Despite challenges such as currency headwinds and a one-off inventory charge, the company improved its cash flow and remains on track to meet its full-year guidance, supported by disciplined cost management and increased customer capex purchases.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £250.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
Oxford Nanopore Technologies Issues Shares Under SIP to CFO
Neutral
Jul 14, 2025

Oxford Nanopore Technologies PLC announced the issuance of 101 ordinary shares to Nick Keher, the company’s Chief Financial Officer, as part of their Share Incentive Plan (SIP). This transaction, conducted on the London Stock Exchange, involves purchasing shares using employees’ gross salaries and matching them with additional shares, reflecting the company’s commitment to employee participation in its growth.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £250.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Business Operations and Strategy
Oxford Nanopore Technologies Releases 2024 Sustainability Report
Positive
Jul 4, 2025

Oxford Nanopore Technologies plc has published its 2024 Sustainability Report, highlighting its commitment to sustainable practices and its impact on society. The report underscores the company’s dedication to providing accessible and scalable molecular analysis technology, which is crucial for various sectors including healthcare and agriculture, thereby reinforcing its market position and stakeholder trust.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £250.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Private Placements and FinancingRegulatory Filings and Compliance
Oxford Nanopore Expands Share Capital with New Equity Issuance
Neutral
Jul 1, 2025

Oxford Nanopore Technologies PLC announced the issuance of 69,871 ordinary shares following the exercise of options under its share option plans and remuneration schemes. These shares have been admitted to the London Stock Exchange, increasing the company’s issued share capital to 961,064,991 ordinary shares, which impacts the total voting rights and shareholder calculations under FCA rules.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £250.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Business Operations and Strategy
Oxford Nanopore Sees Increased Stake by EIT Oxford Holdings
Neutral
Jun 27, 2025

Oxford Nanopore Technologies PLC has announced a change in the voting rights held by EIT Oxford Holdings, LLC, which has increased its stake to 16.09% from a previous 15.09%. This acquisition of voting rights signifies a notable shift in shareholder influence, potentially impacting the company’s strategic decisions and governance. The change reflects ongoing interest and investment in the company’s innovative sequencing technology, which may influence its market positioning and stakeholder confidence.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Business Operations and StrategyRegulatory Filings and Compliance
Oxford Nanopore Technologies Sees Increase in Major Shareholder Voting Rights
Neutral
Jun 18, 2025

Oxford Nanopore Technologies PLC has announced a change in major holdings, with EIT Oxford Holdings, LLC increasing its voting rights from 14.046% to 15.095%. This adjustment in shareholder voting rights reflects a strategic move that could influence the company’s governance and decision-making processes, potentially impacting its market strategy and stakeholder interests.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
Oxford Nanopore Awards Shares to CFO Under Incentive Plan
Neutral
Jun 12, 2025

Oxford Nanopore Technologies PLC announced a transaction involving its Share Incentive Plan (SIP), where 119 ordinary shares were awarded to Nick Keher, the Chief Financial Officer, as part of his participation in the plan. The transaction, conducted through the SIP Trustee, reflects the company’s commitment to aligning managerial interests with shareholder value, potentially enhancing stakeholder confidence in the company’s governance practices.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Regulatory Filings and Compliance
Oxford Nanopore Sees Change in Major Shareholder Voting Rights
Neutral
Jun 11, 2025

Oxford Nanopore Technologies PLC has announced a change in the voting rights held by Baillie Gifford & Co, a major stakeholder. The voting rights have decreased from 5.04% to 4.97%, reflecting a slight reduction in Baillie Gifford’s stake in the company. This adjustment in holdings may influence the company’s shareholder dynamics and could have implications for its governance and strategic decision-making.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Shareholder MeetingsFinancial Disclosures
Oxford Nanopore Technologies AGM: Resolutions Passed Amid Shareholder Engagement
Neutral
Jun 4, 2025

Oxford Nanopore Technologies plc held its Annual General Meeting, where all proposed resolutions were passed with the required majority. The meeting included the approval of financial reports, director elections, and auditor appointments. Notably, Resolution 12 faced significant opposition, with over 20% of votes against it, prompting the Board to commit to further engagement with shareholders to address concerns. This outcome highlights the company’s ongoing efforts to maintain transparent communication with stakeholders and adapt to shareholder feedback.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £250.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Delistings and Listing ChangesPrivate Placements and Financing
Oxford Nanopore Expands Equity Base with New Share Issuance
Neutral
Jun 3, 2025

Oxford Nanopore Technologies PLC announced the issuance of 540,197 ordinary shares following the exercise of options under its share option plans and remuneration schemes. These shares have been admitted to the London Stock Exchange’s main market, increasing the company’s total voting rights to 960,995,120. This development reflects the company’s ongoing efforts to enhance its equity base and maintain transparency in its shareholder communications.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Business Operations and StrategyRegulatory Filings and Compliance
Oxford Nanopore Sees Increase in Major Holdings by EIT Oxford Holdings
Positive
Jun 2, 2025

Oxford Nanopore Technologies PLC has announced a change in its major holdings, with EIT Oxford Holdings, LLC increasing its voting rights from 13.0576% to 14.046%. This adjustment reflects a strategic move by EIT Oxford Holdings, LLC, a company controlled by Lawrence J. Ellison, indicating increased confidence and investment in Oxford Nanopore’s future prospects. The change in holdings may influence the company’s strategic direction and impact its market positioning, potentially affecting stakeholders and investors.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Oxford Nanopore Unveils Major Technology Updates at London Calling Conference
Positive
May 22, 2025

Oxford Nanopore Technologies plc presented significant updates at their annual London Calling conference, showcasing advancements in their molecular sensing platform. Key updates include enhancements in product performance, analytics, and direct RNA sequencing, as well as a focus on regulated product pipelines and proteomics. These developments aim to improve the company’s competitive edge and expand its applications in biopharma and clinical markets, potentially impacting stakeholders by broadening the scope of molecular analysis and increasing adoption in applied markets.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Executive/Board ChangesRegulatory Filings and Compliance
Oxford Nanopore Awards Shares to CFO Under Incentive Plan
Neutral
May 14, 2025

Oxford Nanopore Technologies plc has announced a transaction involving the Share Incentive Plan (SIP), where 112 ordinary shares were awarded to Nick Keher, the Chief Financial Officer, as part of a purchase using his gross salary. The company also issued 112 matching shares to the SIP Trustee to satisfy the award under the SIP. This move is part of the company’s compliance with the UK Market Abuse Regulation, reflecting its commitment to transparent managerial practices and aligning employee incentives with company performance.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Delistings and Listing ChangesPrivate Placements and Financing
Oxford Nanopore Expands Equity with New Share Issuance
Neutral
May 1, 2025

Oxford Nanopore Technologies PLC announced the issuance of 5,007,671 ordinary shares following the exercise of options and remuneration schemes, which are now listed on the London Stock Exchange. This increases the company’s total voting rights to 960,454,923, providing a new denominator for shareholders to calculate their interests in accordance with FCA rules.

Executive/Board Changes
Oxford Nanopore Releases Shares to CEO Under LTIP
Neutral
Apr 30, 2025

Oxford Nanopore Technologies PLC announced the release of 42,953 ordinary shares under its Long-Term Incentive Plan (LTIP) to CEO Gordon Sanghera. This release, part of a performance-related award granted in 2021, required Sanghera to sell a portion of the shares to meet tax obligations, with the remaining shares retained. The transaction, conducted on the London Stock Exchange, highlights the company’s ongoing commitment to rewarding its leadership while maintaining transparency in its executive compensation practices.

Shareholder MeetingsFinancial DisclosuresRegulatory Filings and Compliance
Oxford Nanopore Technologies Publishes 2024 Annual Report and Announces 2025 AGM
Neutral
Apr 30, 2025

Oxford Nanopore Technologies plc has released its 2024 Annual Report and Accounts and announced its 2025 Annual General Meeting. The company encourages shareholders to participate in the AGM, which will be held on June 4, 2025, at their Oxford offices. This announcement is part of their compliance with regulatory requirements and provides shareholders with insights into the company’s financial status and governance.

Business Operations and StrategyRegulatory Filings and Compliance
Oxford Nanopore Technologies Sees Increase in Voting Rights by Major Shareholder
Neutral
Apr 24, 2025

Oxford Nanopore Technologies PLC has announced a change in the voting rights held by EIT Oxford Holdings, LLC, which has increased its stake to 13.0576% from a previous 12.1864%. This change signifies a notable shift in shareholder structure, potentially impacting the company’s governance and strategic decisions, as EIT Oxford Holdings, LLC, linked to Lawrence J. Ellison, now holds a significant portion of voting rights.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 22, 2025